Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)

Inclusion Criteria9

• Properly counselled patients with high grade T1 disease who elect for cystectomy
• Properly counselled patients with non-muscle invasive high grade Ta urothelial carcinoma or carcinoma in situ who are unresponsive to intravesical therapy and have elected cystectomy
• cT2-T3 muscle invasive urothelial carcinoma for planned cystectomy
• Patient who have received prior intravesical therapy or multiple TURBTs can be enrolled (data regarding number of previous TURBTs and type of intravesical therapy will be collected).
• Male or female patients age \>=18 years at the time of consent.
• Able and willing to comply with study requirements.
• Patients must have a non-contrast phase component for CT scans of chest/abdomen/pelvis either pre-existing (prior to accrual) or obtained during the screening process.
• Patients who undergo neoadjuvant systemic therapy for muscle invasive disease must be enrolled before starting systemic therapy.
• Ability to understand and willingness to sign a written informed consent and HIPAA authorization document.